Great presentation by our colleague and friend @boutrosand on 2nd day of this Young @AIOMtweet 2023 on melanoma.
🔎 focus on:
1. mRNA vaccine + Pembro promising adjuvant therapy
2. IPI+NIVO 1st standard line even in BRAFm
3. Tebentafusp standard tp for uveal metastatic melanoma
1/3
Just published in @TheLancetOncol the 15-y follow-up data of #GIM2 trial:
✅ Impressive benefit both in #DFS (+8.5%) and #OS (+7%) rates of dose-dense adjuvant CT in high risk breast cancer patients.
Approval of this new combination #immunotherapy for advanced melanoma patients will improve outcomes & likely impact cancer treatment globally. The next step is @TGAgovau approval & consideration by the Pharmaceutical Benefits Advisory Committee (#PBAC) to be funded in Australia.
1/5 Thrilled to share our metanalysis finally published on @ESHRE @OUPMedicine journal #HumReprod aiming to assess the #safety of fertility preservation techniques before and after anticancer treatments in young women with #breastcancer
📃Link: https://t.co/DsjgyeWqt2
Honored to receive the #BFSA2022 award and to present the results of our meta-analysis to such a great audience.
Thanks to my professors and mentors @delmastro_lucia and @matteolambe 🙏🏼
Special thanks to @BlondeauxEva and all the co-authors for the support!
#Immunoterapia vs #Chemioterapia: la prima garantisce una qualità di vita migliore perché stabilizza il #tumore, anche quando non lo riduce.
La metanalisi di @boutrosand e @FSpagnoloMD pubblicata su European Journal of Cancer.
@OncoAlert
Leggi di più: https://t.co/GXDiUnk5fh
#Immunotherapy with immune checkpoint inhibitors is associated with better quality of life than chemotherapy in our meta-analysis of 17 RCTs out now on European Journal of Cancer
Thanks to my co-authors @boutrosand@EnricaTanda@Lucarecco@matteolambe
https://t.co/nHdMTm35xl
Just out the results of our #metanalysis on the use of hormone replacement therapy in #breastcancer survivors.
‼️HR 1.46 for risk of disease recurrence
👉🏻subgroup analyses for subtypes of disease and type of HRT
@M_Tagliamento@matteolambe@OncoAlert#bcsm
https://t.co/RbO9UOsE9k